Tocilizumab and soluble interleukin-6 receptor in V617F somatic mutation and myeloproliferative neoplasm.
作者信息
Pedersen Kasper Mønsted, Çolak Yunus, Hasselbalch Hans Carl, Bojesen Stig Egil, Nordestgaard Børge Grønne
机构信息
Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
The Copenhagen General Population Study, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
出版信息
EClinicalMedicine. 2020 May 3;22:100337. doi: 10.1016/j.eclinm.2020.100337. eCollection 2020 May.
Abstract
摘要
相似文献
1
Tocilizumab and soluble interleukin-6 receptor in V617F somatic mutation and myeloproliferative neoplasm.托珠单抗与可溶性白细胞介素-6受体在V617F体细胞突变和骨髓增殖性肿瘤中的作用
EClinicalMedicine. 2020 May 3;22:100337. doi: 10.1016/j.eclinm.2020.100337. eCollection 2020 May.
2
Loss-of-function polymorphism in reduces risk of V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study.中的功能丧失多态性降低V617F体细胞突变和骨髓增殖性肿瘤的风险：一项孟德尔随机化研究。
EClinicalMedicine. 2020 Feb 19;21:100280. doi: 10.1016/j.eclinm.2020.100280. eCollection 2020 Apr.
3
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.普通人群中的JAK2V617F体细胞突变：骨髓增殖性肿瘤的发生发展及进展速率
Haematologica. 2014 Sep;99(9):1448-55. doi: 10.3324/haematol.2014.107631. Epub 2014 Jun 6.
4
Soluble interleukin-6 receptor in patients with V617F somatic mutation and myeloproliferative neoplasm.伴有V617F体细胞突变和骨髓增殖性肿瘤患者的可溶性白细胞介素-6受体
EClinicalMedicine. 2020 May 3;22:100340. doi: 10.1016/j.eclinm.2020.100340. eCollection 2020 May.
5
JAK2V617F mutation in patients with splanchnic vein thrombosis.JAK2V617F 突变与肠系膜静脉血栓形成。
Dig Dis Sci. 2010 Jun;55(6):1770-7. doi: 10.1007/s10620-009-0933-y. Epub 2009 Aug 19.
6
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.中风患者特定体细胞骨髓增殖性肿瘤突变的风险增加。
Curr Neurovasc Res. 2017;14(3):222-231. doi: 10.2174/1567202614666170619082900.
7
[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].[骨髓增殖性肿瘤中JAK2V617F突变的研究进展]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1329-33.
8
Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).马来西亚经典骨髓增殖性肿瘤（MPN）患者 JAK2 V617F、CALR 和 MPL 突变的临床和实验室特征。
Int J Environ Res Public Health. 2021 Jul 16;18(14):7582. doi: 10.3390/ijerph18147582.
9
Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.在骨髓增殖性肿瘤的小鼠模型中，内皮细胞JAK2V617F突变会导致血栓形成、血管病变和心肌病。
J Thromb Haemost. 2020 Dec;18(12):3359-3370. doi: 10.1111/jth.15095. Epub 2020 Oct 5.
10
Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.通过液滴数字 PCR 定量 JAK2V617F 突变负荷有助于骨髓增殖性肿瘤的诊断。
Int J Lab Hematol. 2021 Aug;43(4):645-650. doi: 10.1111/ijlh.13560. Epub 2021 May 11.
引用本文的文献
1
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer.髓系增殖性肿瘤中的克隆性造血赋予其同时发生血栓和癌症的倾向。
Curr Hematol Malig Rep. 2023 Aug;18(4):105-112. doi: 10.1007/s11899-023-00697-5. Epub 2023 May 24.
2
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.激活的 IL-6 信号通路参与 CALR 突变的 MPN 的发病机制，是其一个新的治疗靶点。
Blood Adv. 2021 Apr 27;5(8):2184-2195. doi: 10.1182/bloodadvances.2020003291.
本文引用的文献
1
Soluble interleukin-6 receptor in patients with V617F somatic mutation and myeloproliferative neoplasm.伴有V617F体细胞突变和骨髓增殖性肿瘤患者的可溶性白细胞介素-6受体
EClinicalMedicine. 2020 May 3;22:100340. doi: 10.1016/j.eclinm.2020.100340. eCollection 2020 May.
2
Loss-of-function polymorphism in reduces risk of V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study.中的功能丧失多态性降低V617F体细胞突变和骨髓增殖性肿瘤的风险：一项孟德尔随机化研究。
EClinicalMedicine. 2020 Feb 19;21:100280. doi: 10.1016/j.eclinm.2020.100280. eCollection 2020 Apr.
3
The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.白细胞介素 6 中和的 sIL-6R-sgp130 缓冲系统在 2 型糖尿病患者中受到干扰。
Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E411-E420. doi: 10.1152/ajpendo.00166.2019. Epub 2019 Jun 25.
4
Interleukin-6: designing specific therapeutics for a complex cytokine.白细胞介素 6：为复杂细胞因子设计特异性治疗药物。
Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4.
5
The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.白细胞介素-6受体Asp358Ala单核苷酸多态性rs2228145使ADAM蛋白酶的蛋白水解转化率增加。
Biochim Biophys Acta. 2014 Sep;1842(9):1485-94. doi: 10.1016/j.bbadis.2014.05.018. Epub 2014 May 27.
Zotero 插件